Clene Inc. Debt Securities, Available-for-sale, Amortized Cost
Clene Inc. (CLNN) had Debt Securities, Available-for-sale, Amortized Cost of $5.00 million as of 2022-12-31, per its 10-Q filed 2023-11-07.
Discontinued › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2023-11-07
- 2022-12-31: Debt Securities, Available-for-sale, Amortized Cost $5.00M.
- 2022-09-30: Debt Securities, Available-for-sale, Amortized Cost $9.02M.
- 2022-06-30: Debt Securities, Available-for-sale, Amortized Cost $19.12M.
- 2022-03-31: Debt Securities, Available-for-sale, Amortized Cost $23.64M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2022-12-31 | $5.00M 10-Q · filed 2023-11-07 |
| 2022-09-30 | $9.02M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $19.12M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $23.64M 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B |